15. The formulation of claim 1, wherein the preservative is sodium benzoate.

16. The formulation of claim 1, wherein the amount of the preservative is about 0.5 to about 1.2 mg/ml.

17. The formulation of claim 1, wherein the preservative is methylparaben or propylparaben or salts thereof.

18. The formulation of claim 17, wherein the amount of the paraben is about 0.1 to about 2 mg/ml.

19. A stable oral liquid formulation, comprising:

(i) about 0.8 to about 1.2 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof;

(ii) about 140 to about 160 mg/ml xylitol;

(iii) a buffer comprising about 0.5 to about 1.2 mg/ml citric acid and about 1.2 to about 1.7 mg/ml sodium citrate;

(iv) about 0.5 to about 1.2 mg/ml sodium benzoate; and

(v) water;

wherein the pH of the formulation is between about 4 and about 5, and wherein the formulation is stable at about 25±5° C. for at least 12 months.

20. A stable oral liquid formulation, comprising:

(i) about 0.5 to about 1% (w/w of solids) lisinopril or a pharmaceutically acceptable salt or solvate thereof;

(ii) about 95 to about 98% (w/w of solids) of a sweetener that is xylitol;

(iii) a buffer comprising about 0.3 to about 0.7% (w/w of solids) citric acid and about 0.7 to about 1.3% (w/w of solids) sodium citrate;

(iv) about 0.4 to about 1.2% (w/w of solids) of a preservative that is sodium benzoate; and

(v) water;

wherein the pH of the formulation is between about 4 and about 5; and wherein the formulation is stable at about 25±5° C. for at least 12 months.

* * * * *